Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2018 | 1 |
2022 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Albumin-Fusion Recombinant FIX in the Management of People with Hemophilia B: An Evidence-Based Review.
Drug Des Devel Ther. 2022 Sep 15;16:3109-3116. doi: 10.2147/DDDT.S236788. eCollection 2022.
Drug Des Devel Ther. 2022.
PMID: 36132333
Free PMC article.
Review.
Albutrepenonacog-alfa (Idelvion(), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a recombinant human albumin, extending the half-life of rFIX even beyond 100 hours. ...Its efficacy and safety were described in the PROLONG-9FP …
Albutrepenonacog-alfa (Idelvion(), CSL Behring) is a recombinant fusion protein in which the recombinant FIX (rFIX) links a re …
The sudden and unexpected appearance of inhibitors in a previously treated severe haemophilia B patient after the switch to albutrepenonacog alpha.
Zanon E, Pasca S, Simioni P.
Zanon E, et al.
Haemophilia. 2018 Sep;24(5):e372-e375. doi: 10.1111/hae.13590. Epub 2018 Aug 8.
Haemophilia. 2018.
PMID: 30088312
No abstract available.
Item in Clipboard
Cite
Cite